AAV producer NewBiologix emerges from stealth with $50M Series A
An AAV-centered biotech has come onto the scene with $50 million in hand, looking to use an in-house platform to produce a common component used in cell and gene therapies.
On Thursday, NewBiologix announced that it is working on a DNA-based platform to address manufacturing issues that come with developing AAV vectors used in advanced therapies. The Swiss company has come out of stealth with a $50 million Series A.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.